Comparison
Tirzepatide is a dual GLP-1/GIP receptor agonist administered weekly; liraglutide is a GLP-1 mono-agonist requiring daily injection. The addition of GIP receptor agonism and the structural half-life extension in tirzepatide translate into substantially greater reported weight loss and less frequent dosing.
Tirzepatide is marketed as Mounjaro (type 2 diabetes) and Zepbound (obesity). Liraglutide is marketed as Victoza (diabetes) and Saxenda (obesity).
| Attribute | Tirzepatide | Liraglutide |
|---|---|---|
| Class | Dual agonist (GLP-1 / GIP) | GLP-1 receptor agonist (mono-agonist) |
| Mechanism | Activates GLP-1 and GIP receptors; GIP agonism modulates adipogenesis and potentiates insulin secretion | Activates GLP-1 receptor only; satiety signalling, insulin secretion, gastric emptying delay |
| Half-life | ~5 days | ~13 hours |
| Dosing frequency | Once weekly (SubQ injection) | Once daily (SubQ injection) |
| Commonly reported doses | 2.5–15 mg/week SubQ (titration-based) | 0.6–3.0 mg/day SubQ |
| Routes | SubQ injection only | SubQ injection only |
| Reported weight loss | ~20% body weight (SURMOUNT-1 phase 3 trial) | ~8% body weight (Saxenda phase 3 trial) |
| Approval status | FDA-approved (Mounjaro, Zepbound) | FDA-approved (Victoza, Saxenda) |
The fundamental mechanistic difference is that tirzepatide activates two incretin receptors (GLP-1 and GIP), while liraglutide activates only the GLP-1 receptor. GIP receptor agonism adds potentiation of insulin secretion through a distinct pancreatic pathway and appears to modulate adipose tissue metabolism, contributing to the greater weight loss observed with tirzepatide. Research has investigated whether GIP's effects on adipogenesis and fat storage, which seemed paradoxical given its lipogenic role, are actually reversed in the context of obesity, where GIP receptor agonism appears to become anti-adipogenic.
Reported weight loss outcomes differ substantially. Phase 3 data from the SURMOUNT-1 trial reported approximately 20% mean body weight reduction with tirzepatide 15 mg weekly. Liraglutide 3.0 mg daily reported approximately 8% mean reduction. This roughly 12-percentage-point difference represents one of the largest efficacy gaps between consecutive generations of weight management agents in the GLP-1 class, and the addition of GIP receptor agonism is the most likely mechanistic explanation.
Dosing convenience also differs significantly. Tirzepatide's half-life of approximately 5 days permits once-weekly administration, while liraglutide's 13-hour half-life requires daily injection to maintain effective plasma concentrations. For research and clinical contexts where dosing burden influences adherence, this difference is practically significant.
Both compounds act on incretin receptors, but tirzepatide extends its activity beyond the GLP-1 receptor:
Tirzepatide's dual agonism was achieved through a novel structure that interacts with both GIP and GLP-1 receptors with different affinities: it functions as a full GIP receptor agonist and a partial GLP-1 receptor agonist, yet produces stronger weight loss than full GLP-1 agonists. This counterintuitive finding has led to ongoing research into how dual agonism produces synergistic rather than merely additive effects.
Research has investigated both compounds for their potential role in type 2 diabetes management, obesity treatment, and cardiovascular risk reduction. Additional areas of investigation include:
Tirzepatide follows a stepwise titration to maximise tolerability:
Liraglutide titration is also stepwise but uses daily administration:
Reported side effects in research and anecdotal accounts include nausea, vomiting, diarrhoea, constipation, and decreased appetite for both compounds, most pronounced during dose escalation. Both carry class-level precautions regarding pancreatitis and thyroid C-cell effects observed in animal studies. Tirzepatide's GIP component may modulate GI tolerability somewhat, and some accounts in the research literature suggest tirzepatide is better tolerated than semaglutide at comparable weight-loss doses, though direct comparative data with liraglutide in equivalent populations is limited.
Tirzepatide and liraglutide are not co-administered. Both activate the GLP-1 receptor, and combining them would not produce additive mechanistic benefit beyond what either achieves alone, while substantially increasing side effect burden. Clinicians and researchers generally select one compound rather than combining GLP-1 pathway agents.
Research contexts commonly favour tirzepatide when maximum reported weight loss efficacy is the primary variable, when once-weekly dosing is preferred, or when the dual GLP-1/GIP mechanism is specifically relevant to the research question. Its phase 3 dataset also includes emerging data in heart failure and NASH that liraglutide's literature does not yet match.
Research contexts where liraglutide remains relevant include investigations into paediatric or adolescent populations (where liraglutide has regulatory approval), comparisons drawing on the older established Saxenda/Victoza literature, or when the GLP-1 mono-agonist mechanism in isolation is the research focus rather than dual agonism.
Research has investigated GIP receptor agonism for its potential role in augmenting the metabolic effects of GLP-1 receptor activation. In the context of obesity, GIP receptor agonism appears to complement GLP-1's satiety and insulin effects through both pancreatic and adipose tissue pathways, producing greater combined weight reduction than GLP-1 agonism alone. The structural half-life extension in tirzepatide also provides more sustained receptor engagement compared to liraglutide's 13-hour half-life.
Yes. Liraglutide remains in clinical use for several reasons: it has a longer post-approval safety record, it is approved for use in adolescents (12+) in some jurisdictions, it has established use in specific populations, and cost or accessibility considerations may favour it in some contexts. It is also relevant for research specifically designed to isolate the GLP-1 mono-agonist mechanism.
Semaglutide sits between liraglutide and tirzepatide in terms of efficacy: it is a GLP-1 mono-agonist (like liraglutide) but with a longer half-life (~7 days) and roughly twice the reported weight loss (~15% vs ~8%) compared to liraglutide. Tirzepatide's addition of GIP agonism then extends efficacy further to approximately 20% mean weight loss in phase 3 trials.
The GI side effect profile (nausea, vomiting, diarrhoea, constipation) is common to both, as it is class-characteristic of GLP-1 receptor agonists. Tirzepatide's additional GIP receptor activity may modulate GI tolerability compared to pure GLP-1 agonists; some research accounts suggest this, though direct comparative trials with liraglutide are limited. Both require careful dose escalation to manage tolerability.